Project Grant R01DA061412
Award Date
7/15/24
Completion Date
5/31/27
Dollars Obligated
$454K
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
The University of Chicago was awarded a $712,167 Project Grant from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The grant will fund research to investigate the mechanisms by which the opioid drug fentanyl activates the carotid body, a sensory organ that regulates breathing, in order to develop therapeutic strategies for mitigating opioid-induced respiratory depression (OIRD) - a major health concern. The project...
This Project Grant award, valued at $671,732, was issued by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The purpose of the award is to evaluate the use of peripherally-acting mu opioid receptor (MOR) antagonists to prevent and reverse fentanyl-induced respiratory depression, a major cause of opioid overdose deaths, while minimizing withdrawal and aversion side effects. Key objectives include assessing peripheral MOR...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director, funded under the Trans-NIH Research Support program (CFDA 93.310), aims to improve understanding of serotonin mechanisms involved in fentanyl-induced respiratory depression. The $1,378,272 award to the Regents of the University of Michigan, with a project period running from June 2024 to April 2027, will support research to: Determine the effect of fentanyl on the activity of serotonin neurons in the...
This $399,536 Project Grant was awarded by the National Institute on Drug Abuse (NIDA), a part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports research to design, synthesize, and test non-opioid drug candidates that can help combat the national opioid crisis, with a focus on reversing the effects of synthetic opioids like fentanyl. The key goals are to: 1) Develop and characterize chemical lead compounds and control...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop new pharmacological treatments to reverse fentanyl overdose. The $475,500 award to Indiana University will fund research to screen a library of cannabidiol (CBD) analogs to identify negative allosteric modulators (NAMs) of the mu opioid receptor (MOR) that can attenuate fentanyl's effects across signaling pathways. The project will...
This $251,250 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) will support research by Yale University examining the cardiorespiratory impacts of the drug combination of fentanyl and xylazine. The research aims to define the dose-response relationships for respiratory depression and cardiovascular effects when these drugs are administered individually and in combination. The project will use an...
This $2,925,374 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to develop a novel reversal agent for treating overdoses from the combination of fentanyl and xylazine. The funded research will study a sequestrant compound that can simultaneously reduce levels of both fentanyl and the animal tranquilizer xylazine in the body, with the goal of restoring respiration and reversing sedation. The award...
This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the broader Drug Use and Addiction Research Programs (CFDA 93.279), is supporting the development of a novel overdose reversal agent by Serodopa Therapeutics, Inc. The $1,539,426 award aims to complete formulation development and preclinical testing to prepare an Investigational New Drug (IND) application for the company's intranasal naloxone derivative. This novel agent is designed to more effectively reverse...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $184,706 to the University of North Carolina at Chapel Hill (UNC-CH) to investigate the impact of fentanyl consumption on noradrenergic plasticity in the basolateral amygdala. The research aims to understand how fentanyl alters brain circuits and neurotransmitters that regulate addiction-like behaviors and negative affect, with a focus on...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is providing $340,000.00 to The Washington University in St. Louis, Missouri to conduct research on the role of the locus coeruleus-noradrenergic (LC-NE) system in fentanyl withdrawal and associated negative affective behaviors. The key objectives of this 2-year research project are to: 1) determine whether fentanyl withdrawal selectively modifies the...